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Brain “fog” is a constellation of symptoms that include reduced cognition, inability to
concentrate and multitask, as well as loss of short and long term memory. Brain “fog”
characterizes patients with autism spectrum disorders (ASDs), celiac disease, chronic
fatigue syndrome, fibromyalgia, mastocytosis, and postural tachycardia syndrome
(POTS), as well as “minimal cognitive impairment,” an early clinical presentation of
Alzheimer’s disease (AD), and other neuropsychiatric disorders. Brain “fog” may be
due to inflammatory molecules, including adipocytokines and histamine released from
mast cells (MCs) further stimulating microglia activation, and causing focal brain
inflammation. Recent reviews have described the potential use of natural flavonoids for
the treatment of neuropsychiatric and neurodegenerative diseases. The flavone luteolin
has numerous useful actions that include: anti-oxidant, anti-inflammatory, microglia
inhibition, neuroprotection, and memory increase. A liposomal luteolin formulation in olive
fruit extract improved attention in children with ASDs and brain “fog” in mastocytosis
patients. Methylated luteolin analogs with increased activity and better bioavailability
could be developed into effective treatments for neuropsychiatric disorders and brain
“fog.”
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Introduction
Brain “fog” is a constellation of symptoms that include reduced mental acuity and cognition,
inability to concentrate and multitask, as well as loss of short and long-term memory. Brain “fog”
characterizes patients with many neuroimmune diseases (Theoharides, 2013a) with celiac disease
(Lebwohl and Ludvigsson, 2014; Lichtwark et al., 2014) chronic fatigue syndrome (Ocon, 2013),
fibromyalgia and tachycardia postural syndrome (POTS) (Ross et al., 2013), as well as those with
autism spectrum disorders (ASDs) and “minimal cognitive impairment,” which is now considered
the early clinical presentation of Alzheimer’s disease (AD) (Drzezga et al., 2011). Moreover, patients
on chemotherapy often experience brain “fog” (Raffa, 2011).
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Brain “fog” is particularly common in patients with systemic
mastocytosis (SM) (Theoharides et al., 2015c) or disorders of
mast cell (MC) activation (Valent et al., 2012; Petra et al.,
2014). A recent survey of the symptoms experienced by patients
with MC disorders reported that >90% of them experienced
moderate to severe brain “fog” almost daily (Moura et al.,
2012) and cognitive impairment was confirmed using a validated
instrument (Moura et al., 2012). Patients with MC disorders
also experience other related neurologic (Smith et al., 2011)
and psychiatric (Moura et al., 2014) symptoms. It is interesting
that children with mastocytosis were reported to have increased
risk of developing ASDs compared to the general population
(Theoharides, 2009). Children with ASDs are also characterized
by brain “fog” (Rossignol and Frye, 2012) and focal brain
inflammation (Theoharides et al., 2013) with MC activation
being implicated in their pathogenesis (Theoharides et al., 2012a;
Theoharides, 2013b).
Even though AD has typically been associated with brain
senile plaques and neurofibrillary tangles that involve amyloid-
β (Aβ) and tau proteins (Heneka et al., 2015), recent evidence
indicates that oxidative stress/mitochondrial dysfunction (Zhu
et al., 2012) and inflammation (Tan and Seshadri, 2010; Pizza
et al., 2011; Heneka et al., 2015), are possibly involved in AD.
In fact the immune system and inflammation are increasingly
implicated in neuropsychiatric diseases (Kerr et al., 2005;
Schmidt et al., 2007; Hamdani et al., 2013; Jones and Thomsen,
2013; Munkholm et al., 2013).
Pathogenesis/Focal Inflammation
Inflammatory molecules, secreted in the brain could contribute
to the pathogenesis of such diseases (Theoharides et al.,
2004b) possibly including brain “fog.” Brain expression of pro-
inflammatory genes was increased in the brains of deceased
patients with neuropsychiatric diseases (Theoharides et al.,
2011b).
It is still not clear what triggers brain inflammation. Mounting
evidence suggests that stress (Theoharides et al., 2011b) and
exposure to mold (Crago et al., 2003; Shoemaker and House,
2006; Reinhard et al., 2007; Shenassa et al., 2007; Empting, 2009),
especially airborne mycotoxins (Rea et al., 2003; Gordon et al.,
2004; Kilburn, 2009; Brewer et al., 2013), may be involved. It is
interesting that mold can potentiate histamine release from MCs
(Larsen et al., 1996).
In fact, cross-talk between MCs and microglia is being
considered critical in the pathogenesis of neurodegenerative
diseases (Skaper et al., 2012, 2013) (Figure 1). Microglia
activation is a common finding in brains of children with ASDs
(Pardo et al., 2005; Sandoval-Cruz et al., 2011; Gupta et al., 2014),
as well as in other psychiatric diseases (Beumer et al., 2012).
Activation of microglia directly or indirectly by corticotropin-
releasing hormone (CRH) could contribute to the pathogenesis
of mental disorders (Kritas et al., 2014b).
Obesity
Obesity has been associated with neuropsychiatric disorders
(Severance et al., 2012; Byrne et al., 2015). Adipocytokines
are involved in neuroinflammation (Aguilar-Valles et al., 2015)
and possibly in dementia (Arnoldussen et al., 2014; Kiliaan
et al., 2014) including AD (Mathew et al., 2011; Khemka et al.,
2014).
MCs have been implicated in obesity (Theoharides et al.,
2011a), obesity-related asthma (Sismanopoulos et al., 2013)
and in cardiovascular disease (CAD) (Alevizos et al., 2013;
Chrostowska et al., 2013), which involves local inflammation
(Libby et al., 2002; Matusik et al., 2012; Spinas et al., 2014).
Both MCs (Kovanen et al., 1995; Laine et al., 1999) and
histamine (Sakata et al., 1996) have been reported to be
increased in atherosclerotic coronary plaques (Theoharides et al.,
2011a). MC-derived histamine is a coronary constrictor. MC-
derived IL-6 and TNF are independent risk factors for CAD
(Libby et al., 2002) and can be released from MCs under
stress (Huang et al., 2003), which can precipitate myocardial
infarction (Alevizos et al., 2013). Obesity leads to endothelial
dysfunction and chronic inflammation (Iantorno et al., 2014),
also associated with the metabolic syndrome (Sun et al.,
2015).
Role of Mast Cells
MCs derive from bone marrow progenitors, mature in tissues
depending onmicroenvironmental conditions and are critical for
the development of allergic reactions, but also immunity (Galli
et al., 2008b; Theoharides et al., 2010a; Sismanopoulos et al.,
2012), neuroinflammation (Theoharides and Cochrane, 2004;
Theoharides et al., 2010a; Skaper et al., 2012), and mitochondrial
health (Theoharides et al., 2011b; Zhang et al., 2011). MCs can
produce both pro- and anti-inflammatory mediators rendering
capable to exert immuno-modulatory functions (Galli et al.,
2008a; Kalesnikoff and Galli, 2008).
MCs are present in the brain where they regulate blood-
brain barrier (BBB) permeability (Theoharides, 1990) and brain
function (Nautiyal et al., 2008). MCs are located adjacent to
CRH-positive neurons in the rat median eminence (Theoharides
et al., 1995) and regulate the HPA axis (Theoharides et al., 2004a;
Theoharides and Konstantinidou, 2007).
In addition to IgE and antigen (Blank and Rivera, 2004),
MCs are activated by substance P (SP) (Zhang et al., 2011),
neurotensin (NT) (Donelan et al., 2006), and nerve growth factor
(NGF) (Kritas et al., 2014a). In fact, allergic MC stimulation
leads to secretion of Hemokin 1, which acts in an autocrine
manner through MC NK1 receptors to augment IgE-mediated
allergic responses (Sumpter et al., 2015). MC stimulation by
SP is augmented by IL-33 (Theoharides et al., 2010b), which
has been considered an “alarmin” acting through MCs to alert
the innate immune system (Moussion et al., 2008; Enoksson
et al., 2011). IL-33 has been linked to autoimmune and
inflammatory diseases (Theoharides et al., 2015c), especially
brain inflammation (Chakraborty et al., 2010) and recently
AD pathogenesis (Xiong et al., 2014). Antigen can also act
synergistically with toll-like receptors (TLR-2 and TLR-4) to
produce MC cytokines (Qiao et al., 2006) and regulate responses
to pathogens (Abraham and St John, 2010; Theoharides,
2015).
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FIGURE 1 | Schematic representation of the cross-talk between mast cells, microglia, and neurons.
Once activated, MCs secrete numerous vasoactive,
neurosensitizing and pro-inflammatory mediators (Theoharides
et al., 2015a). These include preformed histamine, serotonin,
kinins, proteases and tumor necrosis factor (TNF), as well as
newly synthesized, leukotrienes, prostaglandins, chemokines
(CCXL8, CCL2), cytokines (IL-4, IL-6, IL-1, TNF) and vascular
endothelial growth factor (VEGF), which increase BBB
permeability (Theoharides et al., 2008). MCs store pre-formed
TNF in secretory granules from which it is released rapidly
(Zhang et al., 2012b) and stimulates activated T cells (Nakae
et al., 2006; Kempuraj et al., 2008).
MCs can release some mediators, such as IL-6, selectively
without degranulation (Theoharides et al., 2007). In addition,
CRH can stimulate selective release of VEGF (Cao et al., 2005)
and IL-1 can stimulate selective release of IL-6 (Kandere-
Grzybowska et al., 2003), which could affect brain function
(Theoharides et al., 2004a) and activate the HPA axis
(Kalogeromitros et al., 2007). MC-derived IL-6 along with
TGFβ stimulate development of Th-17 cells (Nakae et al., 2007)
and MCs, themselves secrete IL-17 (Nakae et al., 2007), which
is involved in autoimmunity. Levels of IL-6 were increased in
the cerebrospinal fluid (CSF) (Li et al., 2009b) and plasma (Yang
et al., 2015) of patients with ASDs. MCs can therefore participate
in neuroinflammation (Theoharides and Cochrane, 2004; Zhang
et al., 2012a; Dong et al., 2014), especially autism (Theoharides
et al., 2012a, 2015b; Theoharides, 2013b).
Maternal administration of the viral substitute poly (I:C)
produced autism-like behavior in mice that was dependent on
IL-6 (Hsiao et al., 2012) and was absent in IL-6 knock-out mice
(Smith et al., 2007). We had shown that acute immobilization
stress significantly increased serum IL-6 and this was absent in
MC deficient mice (Huang et al., 2003). It was recently reported
that plasma IL-6 was significantly increased after social stress,
especially in mice that developed a phenotype susceptible to
stress, while IL-6−/− mice were resilient to social stress (Hodes
et al., 2014).
MCs can secrete the content of individual granules
(Theoharides and Douglas, 1978), and biogenic amines such as
serotonin selectively without degranulation (Theoharides et al.,
1982). MCs can communicate with neurons by transgranulation
(Wilhelm et al., 2005). It was recently shown that MCs can
undergo “polarized” exocytosis of proteolytic enzymes is
what has been termed “antibody-dependent degranulation
synapse” (Joulia et al., 2015). MCs can also secrete phospholipid
nanovesicles (exosomes) (Skokos et al., 2002) that could cary a
number of biologically active molecules (Shefler et al., 2011), in a
manner guided by surface antigens (Bryniarski et al., 2013). Such
exosomes could participate in neuropsychiatric diseases (Tsilioni
et al., 2014; Kawikova and Askenase, 2015). In fact, individual
MCs have been shown to exhibit “circadian clock” reactivity
(Molyva et al., 2014; Nakao et al., 2015).
Histamine
MCs are located perivascularly in close proximity to brain
neurons especially in the leptomeninges (Rozniecki et al., 1999a)
and hypothalamus (Pang et al., 1996) where they contain most
of the brain histamine (Alstadhaug, 2014). Increasing evidence
indicates that brain histamine is involved in the pathogenesis of
neuropsychiatric diseases (Haas et al., 2008; Shan et al., 2015)
and the disruption of the BBB (Banuelos-Cabrera et al., 2014),
through MC activation (Esposito et al., 2001, 2002; McKittrick
et al., 2015). Histamine may be important for alertness and
motivation (Zlomuzica et al., 2008; Torrealba et al., 2012), as well
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as cognition, learning and memory (Kamei and Tasaka, 1993;
Alvarez et al., 2001; Rizk et al., 2004; da Silveira et al., 2013). For
instancee, there was enhanced spatial learning and memory in
histamine 3 (H3) receptor mice−/− (Rizk et al., 2004). Moreover,
antagonism of the autoinhibitory H3 receptor improved memory
retention (Orsetti et al., 2001). In fact, H3 antagonists are being
considered for the treatment of cognitive disorders and AD
(Brioni et al., 2011).
It appears that some histamine is necessary for alertness,
learning and motivation, but too much histamine shuts the
system down, in MCs and histaminergic neurons, by activating
H3 autoinhibitory receptors leading to brain “fog” (Table 1).
Brain histamine can be increased by triggers of brain MCs,
by histamine-containing foods (Bodmer et al., 1999; Maintz
and Novak, 2007; Schwelberger, 2010; Prester, 2011), histamine
produced by bacteria (Landete et al., 2008), or overuse of H1
receptor antagonists that would shift histamine binding from H1
to H3 receptors leading to autoinhibition of histamine synthesis
and release (Table 1). In fact, we had shown that in rats at least
only brain MCs express functional H3 receptors (Rozniecki et al.,
1999b), as evidenced by the fact that an H3 receptor agonist
inhibited while at H3 receptor antagonist augmented histamine
and serotonin release only from brain, but not peritoneal MCs.
Beneficial Effect of Luteolin
Recent reviews have discussed the potential use of flavonoids for
the treatment of neuropsychiatric (Jager and Saaby, 2011; Grosso
et al., 2013) and neurodegenerative (Jones et al., 2012; Solanki
et al., 2015) diseases including AD (Sheikh et al., 2012; Baptista
et al., 2014; Mecocci et al., 2014; Vauzour, 2014).
Flavonoids (Figure 2) are naturally occurring compounds
mostly found in green plants and seeds (Middleton et al., 2000).
Unfortunately, our modern life diet contains progressively fewer
flavonoids and under these conditions, the average person cannot
consume enough to make a positive impact on health. Moreover,
less than 10% of orally ingested flavonoids are absorbed
(Passamonti et al., 2009; Thilakarathna and Rupasinghe, 2013)
and are extensively metabolized to inactive ingredients in the
liver (Chen et al., 2014).
Luteolin (5,7-3′5′-tetrahydroxyflavone) has potent
antioxidant, anti-inflammatory (Middleton et al., 2000) and
MC inhibitory activities (Kimata et al., 2000; Kempuraj et al.,
2005; Asadi et al., 2010) and also inhibits auto-immune T
cell activation (Verbeek et al., 2004; Kempuraj et al., 2008)
(Table 2). Luteolin also inhibits microglial IL-6 release (Jang
et al., 2008), microglial activation and proliferation (Chen
et al., 2008; Dirscherl et al., 2010; Kao et al., 2011), as well as
microglia-induced neuron apoptosis (Zhu et al., 2011).
A methylated luteolin analog (6-Methoxyluteolin) was
shown to inhibit IgE-stimulated histamine release from human
basophilic KU812F (Shim et al., 2012). Moreover, we recently
showed that tetramethoxyluteolin is more potent inhibitor of
human cultured MCs than luteolin (Weng et al., 2014).
Luteolin is protective against methylmercury-induced
mitochondrial damage (Franco et al., 2010), as well as mercury
and mitochondrial DNA-triggering of MCs (Asadi et al.,
2010).
FIGURE 2 | structures of (A) Flavone and (B) Luteolin.











Prevents autism-like behavior in mice
Improves attention and sociability in children with ASDs
OLIVE FRUIT EXTRACT
Olive oil increases spatial memory
Hydroxytyrosol increases short-term memory
Oleocanthal inhibits amyloid-induced neurotoxicity
TABLE 1 | Effect of histamine on brain function.




Low Increased diamine oxidase activity Activation of H3 autoinhibitory receptors shuts
down histamine synthesis and release
++ N/A
Normal +++ N/A
High Mast cell secretion, histamine containing foods,
gut bacterial histamine production
Excessive use of H1 receptor antagonists + +++
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Luteolin improved spatial memory in a scopolamine-induced
model (Yoo et al., 2013) and in amyloid β-peptide-induced
toxicity (Liu et al., 2009) in rats. Luteolin was also shown to
induce the synthesis and secretion of neurotrophic factors in
cultured rat astrocytes (Xu et al., 2013). The related flavonoid
7,8-dihydroxyflavone mimicked the activity of brain-derived
neurotrophic factor (BDNF) (Jang et al., 2010b). Moreover, the
related flavonoids 4′-methoxyflavone and 3′,4′-dimethoxyflavone
were shown to be neuroprotective (Fatokun et al., 2013). Luteolin
also protected again cognitive dysfunction induced by chronic
cerebral hypoperfusion is rats (Hagedorn et al., 2010; Fu et al.,
2014) and high fat-diet-induced cognitive dysfunction in mice
(Liu et al., 2014). Furthermore, luteolin (Liu et al., 2009; Jang
et al., 2010a; Yoo et al., 2013) increased memory and inhibited
autism-like behavior in a mouse model of autism (Parker-Athill
et al., 2009). The luteolin structurally related flavonol quercetin
protected against amyloid β-induced neurotoxicity (Liu et al.,
2013; Regitz et al., 2014) and improved cognition in a mouse
model of AD (Wang et al., 2014). In fact, quercetin-o-glucuronide
reduced the generation of β-amyloid in primary cultured neurons
(Ho et al., 2013).
A luteolin containing formulation significantly improved
attention and behavior in children with autism (Theoharides
et al., 2012b; Taliou et al., 2013). This dietary supplement contains
luteolin (100mg per softgel capsule, >98% pure) formulated in
olive fruit extract (<0.001 oleic acid acidity and water content),
which increases oral absorption.
Olive fruit extract contains hydroxytyrosol, which has been
reported to protect against brain hypoxia (Gonzalez-Correa et al.,
2008) and oleocanthal, which inhibits fibrilization of tau proteins
(Li et al., 2009a) and reduces aggregation of Aβ oligomers (Pitt
et al., 2009) implicated in AD. Moreover, olive oil (Mohagheghi
et al., 2010) and olive leaf extract (Mohagheghi et al., 2011)
reduced BBB permeability. Data from animal studies indicate
that use of olive oil (Tsai et al., 2007; Farr et al., 2012; Martinez-
Lapiscina et al., 2013) increased memory.
Flavonoids have been proposed as possible therapeutic agents
for CAD (Kempuraj et al., 2005; Perez-Vizcaino and Duarte,
2010; Yap et al., 2010). A meta analysis of epidemiological
studies showed an inverse relationship between flavonol/flavone
intake and CAD (Perez-Vizcaino and Duarte, 2010). A
review of publications from European and US population
cohorts reported that consumption of flavonoids was strongly
associated with lower CAD mortality (Peterson et al., 2012).
A double-blind, placebo-controlled, randomized clinical study
using the polyhenolic compound Pycnogenol showed improved
endothelial function in patients with CAD (Enseleit et al., 2012)
and a study of 2-week consumption of a polyphenolic drink
lowered urinary biomarkers of CAD (Mullen et al., 2011).
Luteolin suppressed adipocyte activation of macrophages,
inhibited endothelial inflammation (Ando et al., 2009; Deqiu
et al., 2011), increased insulin sensitivity of the endothelium
(Deqiu et al., 2011), and prevented niacin-induced flush
(Kalogeromitros et al., 2008; Papaliodis et al., 2008). Luteolin also
protected low density lipoprotein from oxidation (Brown and
Rice-Evans, 1998) and improved experimentally diet-induced
obesity and insulin resistance (Xu et al., 2014), as well as
protected against high fat-diet induced cognitive deficits (Liu
et al., 2014) in mice.
Mechanism of Flavonoid Action
Luteolin inhibits multiple signaling steps including PI3K,
NFκB, PKCθ, STAT3, and intracellular calcium ions (Kempuraj
et al., 2005; Lopez-Lazaro, 2009). Flavonoids also inhibit MC
degranulation by interacting with distinct vesicle-dependent
SNARE complexes (Yang et al., 2013). It was recently reported
that certain flavonoids inhibited cytokine expression in mouse
bone marrow-derived mast cell by interfering with IL-33
signaling (Funakoshi-Tago et al., 2015).
Flavonoids can also inhibit acetylcholinesterase (Tsai et al.,
2007; Boudouda et al., 2015), which will increase acetylcholine
and improve memory (Table 1). It is of interest that luteolin
further inhibits release of the excitatory neurotransmitter
glutamate (Lin et al., 2011), while it activates receptors for
the inhibitory neurotransmitter γ-amino butyric acid (GABA)
independent of GABA, suggesting it may also have a calming
effect (Hanrahan et al., 2011). In fact, benzodiazepines that act by
activating GABA receptors were shown to bind to MCs (Miller
et al., 1988).
Conclusion
Presently, 1 in 20 individuals over the age of 65 has dementia,
while just the European population over 65 will rise from 17.4%
in 2010 to 24% in 2030 or about 200 million people (United
Nations Department of Economic and Social Affairs Population
Division, 2015). The cost of caring for AD patients in the US is
estimated to be $220 billion per year (Alzheimers Association,
2015). These numbers do not include brain “fog” present in
the others disorders discussed. For instance, the cost of ASDs
to the US economy is estimated at $ 180 billion per year. It
is therefore obvious that any effective treatment will make a
significant difference both to the health of the patients and to the
economy. However, in spite of intensive research, clinical trials
targeting Aβ have failed (Corbett et al., 2012) necessitating new
therapeutic targets and there are no effective treatments for the
other neuropsychiatric disorders discussed.
Flavonoids are generally considered safe (Kawanishi et al.,
2005; Harwood et al., 2007; Seelinger et al., 2008; Corcoran
et al., 2012; Theoharides et al., 2014). Unfortunately, some of
the cheaper sources of flavonoids found in dietary supplements
are from peanut shells and fava beans and may lead to
anaphylactic reactions or hemolytic anemia to allergic and
G6PD-deficient individuals, respectively. Flavonoids are
extensively metabolized (Chen et al., 2014) primarily through
glucoronidation, methylation, and sulphation (Hollman et al.,
1995; Hollman and Katan, 1997). Therefore, flavonoids must
be used with caution when administered with other natural
polyphenolic molecules (e.g., curcumin, resveratrol) or drugs
metabolized by the liver as they may affect the blood levels
of themselves or of other drugs (Theoharides and Asadi,
2012). Tetramethoxyluteolin is already methylated and less
likely to affect liver metabolism, is more stable (Walle, 2007),
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and has better bioavailability (Wei et al., 2014). Intranasal
tetramethoxyluteolin preparations would offer the additional
advantage of delivering the flavonoid directly to the brain
through the cribriform plexus as was shown for some other
compounds (Zhuang et al., 2011).
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